These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12814399)

  • 1. Numbers of colony-forming progenitors in patients with systemic mastocytosis: potential diagnostic implications and comparison with myeloproliferative disorders.
    Jordan JH; Jäger E; Sperr WR; Schwarzinger I; Födinger M; Fritsche-Polanz R; Ohler L; Geissler K; Valent P
    Eur J Clin Invest; 2003 Jul; 33(7):611-8. PubMed ID: 12814399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders.
    Horny HP; Ruck M; Wehrmann M; Kaiserling E
    Br J Haematol; 1990 Oct; 76(2):186-93. PubMed ID: 2128807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.
    Jawhar M; Schwaab J; Schnittger S; Sotlar K; Horny HP; Metzgeroth G; Müller N; Schneider S; Naumann N; Walz C; Haferlach T; Valent P; Hofmann WK; Cross NC; Fabarius A; Reiter A
    Leukemia; 2015 May; 29(5):1115-22. PubMed ID: 25567135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
    Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
    J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic evidence for a clonal disorder involving CFU-GEMM, BFU-E and CFU-C in patients with myeloproliferative disorders.
    Sugiyama H; Ichiba S; Okuno Y; Takahashi T; Imura H; Nakamura K; Iho S; Hoshino T; Okada T; Furukawa H
    Nihon Ketsueki Gakkai Zasshi; 1989 Sep; 52(6):1022-32. PubMed ID: 2588952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.
    Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A
    Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.
    Horny HP; Sotlar K; Sperr WR; Valent P
    J Clin Pathol; 2004 Jun; 57(6):604-8. PubMed ID: 15166264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3.
    Kobayashi S; Teramura M; Hoshino S; Motoji T; Oshimi K; Mizoguchi H
    Br J Haematol; 1993 Apr; 83(4):539-44. PubMed ID: 7686030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders.
    Del Cañizo MC; Brufau A; Mota A; Lopez N; Fernandez ME; Vallejo C; Hernandez JM; Garcia JL; San Miguel JF
    Haematologica; 1998 Jan; 83(1):3-7. PubMed ID: 9580461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.
    Wang SA; Hutchinson L; Tang G; Chen SS; Miron PM; Huh YO; Jones DM; Bueso-Ramos C; Verstovsek S; Medeiros LJ; Miranda RN
    Am J Hematol; 2013 Mar; 88(3):219-24. PubMed ID: 23440662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
    Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
    Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).
    Sotlar K; Colak S; Bache A; Berezowska S; Krokowski M; Bültmann B; Valent P; Horny HP
    J Pathol; 2010 Apr; 220(5):586-95. PubMed ID: 20112369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating pluripotent haemopoietic cells in patients with myeloproliferative disorders.
    Douer D; Fabian I; Cline MJ
    Br J Haematol; 1983 Jul; 54(3):373-81. PubMed ID: 6574788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders.
    Hibbin JA; Njoku OS; Matutes E; Lewis SM; Goldman JM
    Br J Haematol; 1984 Jul; 57(3):495-503. PubMed ID: 6743569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of megakaryopoiesis in vitro of paired peripheral blood progenitor cells and bone marrow harvested during remission in patients with acute myeloid leukaemia.
    Briggs M; Adams JA; Brereton ML; Burgess R; Hyde K; Lenehan H; Yin JA
    Br J Haematol; 2001 Dec; 115(3):563-8. PubMed ID: 11736936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of in vitro growth pattern of megakaryocyte progenitors (CFU-M) in myeloproliferative disorders.
    Hamaguchi H; Takano N; Sakamaki H; Enokihara H; Saito K; Furusawa S; Shishido H
    Eur J Haematol; 1988 Aug; 41(2):163-9. PubMed ID: 3410010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
    Valent P
    Hematology Am Soc Hematol Educ Program; 2015; 2015():98-105. PubMed ID: 26637707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7.
    Agis H; Krauth MT; Mosberger I; Müllauer L; Simonitsch-Klupp I; Schwartz LB; Printz D; Böhm A; Fritsch G; Horny HP; Valent P
    J Clin Pathol; 2006 Apr; 59(4):396-402. PubMed ID: 16461568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.